[Advances in immunotherapy of extranodal NK/T cell lymphoma].

Extranodal NK/T-cell lymphoma (ENKTCL) is a relatively rare group of highly aggressive non-Hodgkin's lymphoma (NHL). The disease has rapid clinical progress, high degree of malignancy and poor prognosis. Traditional chemoradiotherapy regimens have not shown good efficacy. In recent years, the immunotherapy of tumors has developed rapidly. At present, it has shown strong therapeutic activity in the treatment of various solid tumors such as non-small cell lung cancer, prostate cancer, melanoma and kidney cancer. Multiple tumor immunotherapy drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. This article reviews recent novel immunotherapeutic regimens of ENKTCL, hoping to change the treatment modality of this malignant disease.

Determination of serum selenium by hydride generation flame atomic absorption spectrometry.

Serum is rapidly digested with a mixture of nitric and perchloric acids at a temperature of 180 +/- 10 degrees C, and hydrochloric acid is used to reduce selenium(VI) to selenium(IV). Selenium is determined by hydride generation flame atomic absorption spectrometry. The results show that this method has the advantages of being sensitive, accurate, rapid and simple. After the serum is digested and diluted, 4.0 ml is taken for the determination. The characteristic concentration, detection limit, variation coefficient, recovery rate and linear range are 2.93 mug 1(-1), 1.55 mug l(-1), 1.6-5.0%, 97.3-99.2% and 0.0-320.0 mug l(-1) respectively. Serum at 4 degrees C and in frozen state can be preserved for at least 7 and 14 days, respectively.